Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study

Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for the treatment of adults with chronic immune thrombocytopenia (ITP). Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuter, David J., Rogers, Kerry A., Boxer, Michael A., Choi, Michael, Agajanian, Richy, Arnold, Donald M., Broome, Catherine M., Field, Joshua J., Murakhovskaya, Irina, Numerof, Robert, Tong, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313871/
https://www.ncbi.nlm.nih.gov/pubmed/35179251
http://dx.doi.org/10.1002/ajh.26508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313871/
https://www.ncbi.nlm.nih.gov/pubmed/35179251
http://dx.doi.org/10.1002/ajh.26508

Ejemplares similares